Morgan Stanley Maintains Overweight on CME Group, Lowers Price Target to $324

Benzinga Newsdesk www.benzinga.com Negative 91.5%

Neg 91.5% Neu 0% Pos 0%

Morgan Stanley analyst Michael Cyprys maintains CME Group (NASDAQ:CME) with a Overweight and lowers the price target from $353 to $324.